Apologies for the long wait since our own Dr. Weiss’s upbeat and thoughtful review of the leading stories about lung cancer in 2011. Dr. Weiss covered a lot of ground in his presentation that was followed by a Q&A session, so we’ve broken that up into several short pieces that cover a few highlights at a time. In fact, we’re going to make an effort to have podcasts shorter and easier to digest in the future.
The first part is on EGFR-based therapies, including the EURTAC trial of the EGFR tyrosine kinase inhibitor (TKI) Tarceva (erlotinib) vs. standard doublet chemo in a European, EGFR mutation-positive patient population, followed by work on EGFR TKI/monoclonal antibody combinations: one being the single arm afatinib/Erbitux (cetuximab) for patients with acquired resistance after a good response to earlier EGFR TKI therapy, and the second being Tarceva with either the c-MET antibody MET-MAb or placebo.
Here’s the audio and video versions of the podcast, along with the transcript and figures for this portion of the program.
We’ll be putting out more pieces of this every few day or two, so look for the next part very soon. Thanks to Dr. Weiss, and also to LUNGevity Foundation for partnering with us to make this program possible.